On July 16, 2026, Gain Therapeutics, Inc. (Nasdaq: GANX) based in Bethesda, Md., a biotech firm advancing allosteric small molecule therapies, issued a shareholder letter from CEO Gene Mack. This communication outlines the company's progress in the clinical-stage development of innovative therapies.